Skip to main content
Top
Published in: BMC Gastroenterology 1/2008

Open Access 01-12-2008 | Correspondence

Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors

Authors: Lauren B Gerson, George Triadafilopoulos, Peyman Sahbaie, Winston Young, Sheldon Sloan, Malcolm Robinson, Philip B Miner Jr, Jerry D Gardner

Published in: BMC Gastroenterology | Issue 1/2008

Login to get access

Abstract

Background

A Stanford University study reported that in asymptomatic GERD patients who were being treated with a proton pump inhibitor (PPI), 50% had pathologic esophageal acid exposure.

Aim

We considered the possibility that the high prevalence of pathologic esophageal reflux might simply have resulted from calculating acidity as time pH < 4.

Methods

We calculated integrated acidity and time pH < 4 from the 49 recordings of 24-hour gastric and esophageal pH from the Stanford study as well as from another study of 57 GERD subjects, 26 of whom were treated for 8 days with 20 mg omeprazole or 20 mg rabeprazole in a 2-way crossover fashion.

Results

The prevalence of pathologic 24-hour esophageal reflux in both studies was significantly higher when measured as time pH < 4 than when measured as integrated acidity. This difference was entirely attributable to a difference between the two measures during the nocturnal period. Nocturnal gastric acid breakthrough was not a useful predictor of pathologic nocturnal esophageal reflux.

Conclusion

In GERD subjects treated with a PPI, measuring time esophageal pH < 4 will significantly overestimate the prevalence of pathologic esophageal acid exposure over 24 hours and during the nocturnal period.
Appendix
Available only for authorised users
Literature
1.
go back to reference Milkes D, Gerson LB, Triadafilopoulos G: Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol. 2004, 99: 991-996. 10.1111/j.1572-0241.2004.30124.x.CrossRefPubMed Milkes D, Gerson LB, Triadafilopoulos G: Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD). Am J Gastroenterol. 2004, 99: 991-996. 10.1111/j.1572-0241.2004.30124.x.CrossRefPubMed
2.
go back to reference Achem SR: Acid inhibition in GERD – How much is enough?. Am J Gastroenterol. 2004, 99: 997-999. 10.1111/j.1572-0241.2004.40316.x.CrossRefPubMed Achem SR: Acid inhibition in GERD – How much is enough?. Am J Gastroenterol. 2004, 99: 997-999. 10.1111/j.1572-0241.2004.40316.x.CrossRefPubMed
3.
go back to reference Gardner JD, Perdomo C, Sloan S, Hahne WF, Barth JA, Rodriguez-Stanley S, Robinson M: Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther. 2002, 16: 455-464. 10.1046/j.1365-2036.2002.01158.x.CrossRefPubMed Gardner JD, Perdomo C, Sloan S, Hahne WF, Barth JA, Rodriguez-Stanley S, Robinson M: Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther. 2002, 16: 455-464. 10.1046/j.1365-2036.2002.01158.x.CrossRefPubMed
4.
go back to reference Gardner JD, Sloan S, Miner PB, Robinson M: Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003, 17: 945-953. 10.1046/j.1365-2036.2003.01533.x.CrossRefPubMed Gardner JD, Sloan S, Miner PB, Robinson M: Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003, 17: 945-953. 10.1046/j.1365-2036.2003.01533.x.CrossRefPubMed
5.
go back to reference Gardner JD, Young W, Sloan S, Robinson M, Miner PB: The effects of changing temperature correction factors on measures of acidity calculated from gastric and esophageal pH recordings. Aliment Pharmacol Ther. 2006, 23: 629-638. 10.1111/j.1365-2036.2006.02787.x.CrossRefPubMed Gardner JD, Young W, Sloan S, Robinson M, Miner PB: The effects of changing temperature correction factors on measures of acidity calculated from gastric and esophageal pH recordings. Aliment Pharmacol Ther. 2006, 23: 629-638. 10.1111/j.1365-2036.2006.02787.x.CrossRefPubMed
6.
go back to reference Pandolfino JE, Schriener MA, Lee TJ, Zhang Q, Boniquit C, Kahrilas PJ: Comparison of the Bravo™ Wireless and Digitrapper™ Cathete-Based monitoring systems for measuring esophageal acid exposure. Am J Gastroenterol. 2005, 100: 1466-1476. 10.1111/j.1572-0241.2005.41719.x.CrossRefPubMed Pandolfino JE, Schriener MA, Lee TJ, Zhang Q, Boniquit C, Kahrilas PJ: Comparison of the Bravo™ Wireless and Digitrapper™ Cathete-Based monitoring systems for measuring esophageal acid exposure. Am J Gastroenterol. 2005, 100: 1466-1476. 10.1111/j.1572-0241.2005.41719.x.CrossRefPubMed
7.
go back to reference Gardner JD, Sloan S, Miner PB, Robinson M: Determination of the reduction in gastric acidity necessary to prevent pathologic esophageal reflux in GERD patients treated with a proton pump inhibitor. Aliment Pharmacol Ther. 2003, 17: 955-964. 10.1046/j.1365-2036.2003.01532.x.CrossRefPubMed Gardner JD, Sloan S, Miner PB, Robinson M: Determination of the reduction in gastric acidity necessary to prevent pathologic esophageal reflux in GERD patients treated with a proton pump inhibitor. Aliment Pharmacol Ther. 2003, 17: 955-964. 10.1046/j.1365-2036.2003.01532.x.CrossRefPubMed
8.
go back to reference Berry DA: Statistics: A Bayesian Perspective. 1996, Duxbury Press, Belmont Berry DA: Statistics: A Bayesian Perspective. 1996, Duxbury Press, Belmont
9.
go back to reference Schindlbeck NE, Heinrich C, Konig A, Dendorfer A, Pace F, Muller-Lissner SA: Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology. 1987, 93: 85-90.CrossRefPubMed Schindlbeck NE, Heinrich C, Konig A, Dendorfer A, Pace F, Muller-Lissner SA: Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology. 1987, 93: 85-90.CrossRefPubMed
10.
go back to reference Weiner GJ, Morgan TM, Copper JB, Wu WC, Castell DO, Sinclair JW, Richter JE: Ambulatory 24-hour esophageal pH monitoring. Dig Dis Sci. 1988, 33: 1127-1133. 10.1007/BF01535789.CrossRef Weiner GJ, Morgan TM, Copper JB, Wu WC, Castell DO, Sinclair JW, Richter JE: Ambulatory 24-hour esophageal pH monitoring. Dig Dis Sci. 1988, 33: 1127-1133. 10.1007/BF01535789.CrossRef
11.
go back to reference Masclee AAM, De Best ACAM, De Graaf R, Cluysenaer OJJ, Jansen JBMJ: Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1990, 25: 225-230.PubMed Masclee AAM, De Best ACAM, De Graaf R, Cluysenaer OJJ, Jansen JBMJ: Ambulatory 24-hour pH-metry in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol. 1990, 25: 225-230.PubMed
12.
go back to reference Schindlbeck NE, Ippisch H, Klausner AG, Muller-Lissner SA: Which pH threshold is best in esophageal pH monitoring?. Am J Gastroenterol. 1991, 86: 1138-1141.PubMed Schindlbeck NE, Ippisch H, Klausner AG, Muller-Lissner SA: Which pH threshold is best in esophageal pH monitoring?. Am J Gastroenterol. 1991, 86: 1138-1141.PubMed
13.
go back to reference Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, Albertucci : Ambulatory 24-H esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol. 1992, 87: 1102-1111.PubMed Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, Albertucci : Ambulatory 24-H esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol. 1992, 87: 1102-1111.PubMed
14.
go back to reference Ghillebert G, Demeyere AM, Janssens J, Vantrappen G: How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease?. Dig Dis Sci. 1995, 40: 1317-1324. 10.1007/BF02065545.CrossRefPubMed Ghillebert G, Demeyere AM, Janssens J, Vantrappen G: How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease?. Dig Dis Sci. 1995, 40: 1317-1324. 10.1007/BF02065545.CrossRefPubMed
15.
go back to reference Swets JA: Measuring the accuracy of diagnostic systems. Science. 1988, 240: 1285-1293. 10.1126/science.3287615.CrossRefPubMed Swets JA: Measuring the accuracy of diagnostic systems. Science. 1988, 240: 1285-1293. 10.1126/science.3287615.CrossRefPubMed
16.
go back to reference McNeil BJ, Keeler E, Adelstein SJ: Primer on certain elements of medical decision making. New Eng J Med. 1975, 293: 211-215.CrossRefPubMed McNeil BJ, Keeler E, Adelstein SJ: Primer on certain elements of medical decision making. New Eng J Med. 1975, 293: 211-215.CrossRefPubMed
17.
go back to reference Hanley JA, McNeil BJ: A method of comparing the areas under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.CrossRefPubMed Hanley JA, McNeil BJ: A method of comparing the areas under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.CrossRefPubMed
18.
go back to reference Hanley JA, McNeil BJ: The meaning and use of the area under receiver operating characteristic curves derived from the same cases. Radiology. 1983, 148: 839-843.CrossRefPubMed Hanley JA, McNeil BJ: The meaning and use of the area under receiver operating characteristic curves derived from the same cases. Radiology. 1983, 148: 839-843.CrossRefPubMed
19.
go back to reference Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology. 1998, 115: 1335-1339. 10.1016/S0016-5085(98)70010-1.CrossRefPubMed Peghini PL, Katz PO, Castell DO: Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. Gastroenterology. 1998, 115: 1335-1339. 10.1016/S0016-5085(98)70010-1.CrossRefPubMed
20.
go back to reference Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998, 93: 763-767. 10.1111/j.1572-0241.1998.221_a.x.CrossRefPubMed Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998, 93: 763-767. 10.1111/j.1572-0241.1998.221_a.x.CrossRefPubMed
21.
go back to reference Katz PO, Anderson C, Khoury R, Castell DO: Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998, 12: 1231-1234. 10.1046/j.1365-2036.1998.00419.x.CrossRefPubMed Katz PO, Anderson C, Khoury R, Castell DO: Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998, 12: 1231-1234. 10.1046/j.1365-2036.1998.00419.x.CrossRefPubMed
22.
go back to reference Hatlebakk JG, Katz PO, Kuo B, Castell DO: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998, 11: 1235-1240. 10.1046/j.1365-2036.1998.00426.x.CrossRef Hatlebakk JG, Katz PO, Kuo B, Castell DO: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998, 11: 1235-1240. 10.1046/j.1365-2036.1998.00426.x.CrossRef
23.
go back to reference Khoury RM, Katz PO, Hammod R, Castell DO: Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther. 1999, 13: 675-678. 10.1046/j.1365-2036.1999.00499.x.CrossRefPubMed Khoury RM, Katz PO, Hammod R, Castell DO: Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther. 1999, 13: 675-678. 10.1046/j.1365-2036.1999.00499.x.CrossRefPubMed
24.
go back to reference Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003, 98: 545-550. 10.1111/j.1572-0241.2003.07304.x.CrossRefPubMed Ours TM, Fackler WK, Richter JE, Vaezi MF: Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003, 98: 545-550. 10.1111/j.1572-0241.2003.07304.x.CrossRefPubMed
25.
go back to reference Castell D, Bagin R, Goldlust B, Major J, Hepburn B: Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005, 21: 1467-1474. 10.1111/j.1365-2036.2005.02513.x.CrossRefPubMed Castell D, Bagin R, Goldlust B, Major J, Hepburn B: Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005, 21: 1467-1474. 10.1111/j.1365-2036.2005.02513.x.CrossRefPubMed
26.
go back to reference Zerbib F, Roman S, Ropert A, Bruley des Varannes S, Poudeoux P, Chaput U, Mion F, Verin E, Galmiche J-P, Sifrim D: Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006, 101: 1956-1963. 10.1111/j.1572-0241.2006.00711.x.CrossRefPubMed Zerbib F, Roman S, Ropert A, Bruley des Varannes S, Poudeoux P, Chaput U, Mion F, Verin E, Galmiche J-P, Sifrim D: Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006, 101: 1956-1963. 10.1111/j.1572-0241.2006.00711.x.CrossRefPubMed
27.
go back to reference Sontag SJ: Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993, 7: 293-312.CrossRefPubMed Sontag SJ: Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993, 7: 293-312.CrossRefPubMed
28.
go back to reference Katzka DA, Castell DO: Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's esophagus. Am J Gastroenterol. 1994, 89: 989-991.PubMed Katzka DA, Castell DO: Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in Barrett's esophagus. Am J Gastroenterol. 1994, 89: 989-991.PubMed
29.
go back to reference Ouatu-Lascar R, Triadafilopoulos G: Complete elimination of reflux symptoms does not guarantee normalization of intra-esophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998, 93: 711-716. 10.1111/j.1572-0241.1998.211_a.x.CrossRefPubMed Ouatu-Lascar R, Triadafilopoulos G: Complete elimination of reflux symptoms does not guarantee normalization of intra-esophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998, 93: 711-716. 10.1111/j.1572-0241.1998.211_a.x.CrossRefPubMed
30.
go back to reference Fass R, Sampliner RE, Malagon IB, Hayden CW, Camargo L, Wendel CS, Garewal HS: Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther. 2000, 14: 597-602. 10.1046/j.1365-2036.2000.00749.x.CrossRefPubMed Fass R, Sampliner RE, Malagon IB, Hayden CW, Camargo L, Wendel CS, Garewal HS: Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther. 2000, 14: 597-602. 10.1046/j.1365-2036.2000.00749.x.CrossRefPubMed
31.
go back to reference Arnestad JS, Kleveland PM, Waldum HL: In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment Pharmacol Ther. 1997, 11: 355-358. 10.1046/j.1365-2036.1997.300000.x.CrossRefPubMed Arnestad JS, Kleveland PM, Waldum HL: In single doses ranitidine effervescent is more effective than lansoprazole in decreasing gastric acidity. Aliment Pharmacol Ther. 1997, 11: 355-358. 10.1046/j.1365-2036.1997.300000.x.CrossRefPubMed
32.
go back to reference Hedenstrom H, Alm C, Kraft M, Grahnen A: Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther. 1997, 11: 1137-1141. 10.1046/j.1365-2036.1997.00264.x.CrossRefPubMed Hedenstrom H, Alm C, Kraft M, Grahnen A: Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther. 1997, 11: 1137-1141. 10.1046/j.1365-2036.1997.00264.x.CrossRefPubMed
Metadata
Title
Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors
Authors
Lauren B Gerson
George Triadafilopoulos
Peyman Sahbaie
Winston Young
Sheldon Sloan
Malcolm Robinson
Philip B Miner Jr
Jerry D Gardner
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2008
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-8-15

Other articles of this Issue 1/2008

BMC Gastroenterology 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.